You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation
On demand events

ISDS 2023: Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis

Gil Yosipovitch
Lisa Beck
Robert Bissonnette
MD
Gil Yosipovitch +2 more

On demand materials

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch
Dermatology
expert video

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

Skin Dysbiosis in AD
Dermatology
expert video

Skin Dysbiosis in AD

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD
Dermatology
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

The Impact of Skin Dysbiosis on Atopic Dermatitis
Dermatology
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Learning objectives

  • Review the latest evidence on how type 2 inflammation drives skin barrier dysfunction in AD
  • Discuss the evidence illustrating how type 2 inflammation affects the skin microbiome in AD
  • Explore the role of type 2 inflammation in neuroimmune axis dysregulation in AD

Description

At the 2023 Inflammatory Skin Disease Summit in Vienna, ADVENT held a symposium entitled “Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch”, where experts Lisa A. Beck, MD (University of Rochester Medical Center, USA); Robert Bissonnette, MD (Innovaderm Research Inc., Canada); and Gil Yosipovitch, MD (University of Miami, USA) discussed the latest advances in understanding how type 2 inflammation drives skin barrier dysfunction, dysbiosis and itch in atopic dermatitis (AD).

Tags
expert insightsmechanism of diseasesymposium
MAT-GLB-2305527 V1.0 01/2024

About these experts

Dermatology
MD

Gil Yosipovitch

Professor and Stiefel-endowed Chair of Medical Dermatology at the Dr. Phillip Frost Department of Dermatology at the Miller School of Medicine at the University of Miami; Director of the Miami Itch Center, Florida, US

Dermatology
MD

Lisa Beck

Goldsmith Professor of Dermatology, University of Rochester Medical Center, New York, United States

Dermatology
MD

Robert Bissonnette

President of Innovaderm Research, Montréal, Quebec, Canada

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region